Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.
Digital Object Identifier (DOI)
This work was supported by DanceBlue, an effort of the University of Kentucky student community to support pediatric oncology care and research.
Wagner, Lars M., "Fifteen Years of Irinotecan Therapy for Pediatric Sarcoma: Where to Next?" (2015). Pediatrics Faculty Publications. 167.